Strides Targets $200-400m From Generic Injectables In Mid-Term

Insulin Glargine, Lispro In Development

 
• By Vibha Ravi
  
Growth
Strides Chalks Stelis' Growth Strategy • Source: Shutterstock

More from India

More from Focus On Asia